PDF(Pubmed)
Abstract：
UNASSIGNED: Bipolar Affective Disorder (BPAD) merits careful consideration within the medical and healthcare communities, researchers, and policymakers. This is due to its substantial disability burden, elevated prevalence of co-morbidities, heightened lifetime risk of suicidality, and a significant treatment gap. This article focuses on the lifetime and current prevalence, correlates, co-morbidities, associated disabilities, socio-economic impact, and treatment gap for BPAD in the adult population of the National Mental Health Survey (NMHS) 2016.
UNASSIGNED: The NMHS 2016 was a nationally representative study conducted across 12 Indian states between 2014 and 2016. A multi-stage, stratified, random cluster sampling technique based on probability proportionate to size at each stage was used. The diagnosis of BPAD was based on Mini-International Neuropsychiatric Interview 6.0.0. Sheehan\'s Disability Scale was used to assess the disability.
UNASSIGNED: A total of 34,802 adults were interviewed. The overall weighted prevalence of BPAD was 0.3% [95% confidence interval (CI): 0.29-0.31] for current and 0.5% (95% CI: 0.49-0.51) for lifetime diagnosis. Male gender [odds ratio (OR) 1.56] and residence in urban metropolitans (OR 2.43) had a significantly higher risk of a lifetime diagnosis of BPAD. Substantial cross-sectional co-morbidities were noted as per MINI 6.0.0 with the diagnosis of current BPAD such as tobacco use disorder (33.3%), other substance use disorders (14.6%), and anxiety disorders (10.4%). Two-thirds of persons with current BPAD reported disability of varying severity at work (63%), social (59.3%), and family life (63%). The treatment gap for current BPAD was 70.4%.
UNASSIGNED: Most individuals with current BPAD reported moderate-severe disability. There were substantial co-morbidities and a large treatment gap. These warrant concentrated efforts from policymakers in devising effective strategies.
UNASSIGNED: The NMHS 2016 was a nationally representative study conducted across 12 Indian states between 2014 and 2016. A multi-stage, stratified, random cluster sampling technique based on probability proportionate to size at each stage was used. The diagnosis of BPAD was based on Mini-International Neuropsychiatric Interview 6.0.0. Sheehan\'s Disability Scale was used to assess the disability.
UNASSIGNED: A total of 34,802 adults were interviewed. The overall weighted prevalence of BPAD was 0.3% [95% confidence interval (CI): 0.29-0.31] for current and 0.5% (95% CI: 0.49-0.51) for lifetime diagnosis. Male gender [odds ratio (OR) 1.56] and residence in urban metropolitans (OR 2.43) had a significantly higher risk of a lifetime diagnosis of BPAD. Substantial cross-sectional co-morbidities were noted as per MINI 6.0.0 with the diagnosis of current BPAD such as tobacco use disorder (33.3%), other substance use disorders (14.6%), and anxiety disorders (10.4%). Two-thirds of persons with current BPAD reported disability of varying severity at work (63%), social (59.3%), and family life (63%). The treatment gap for current BPAD was 70.4%.
UNASSIGNED: Most individuals with current BPAD reported moderate-severe disability. There were substantial co-morbidities and a large treatment gap. These warrant concentrated efforts from policymakers in devising effective strategies.
摘要：
■双相情感障碍（BPAD）值得在医疗和医疗保健社区中仔细考虑，研究人员,和政策制定者。这是由于其严重的残疾负担，合并症患病率升高，终生自杀风险增加，和显著的治疗差距。本文重点介绍了终生和当前的患病率，相关性，合并症,相关残疾,社会经济影响,以及2016年全国心理健康调查(NMHS)成年人群中BPAD的治疗差距。
■NMHS2016是一项具有全国代表性的研究，在2014年至2016年期间在印度12个州进行。一个多阶段，分层，在每个阶段使用基于与大小成比例的概率的随机整群抽样技术。BPAD的诊断基于迷你国际神经精神病学访谈6.0.0。使用Sheehan的残疾量表评估残疾。
■共采访了34,802名成年人。目前BPAD的总体加权患病率为0.3％[95％置信区间（CI）：0.29-0.31]，终生诊断为0.5％（95％CI：0.49-0.51）。男性[优势比（OR）1.56]和居住在城市大都市（OR2.43）的终生诊断为BPAD的风险明显更高。根据MINI6.0.0，在诊断当前的BPAD如烟草使用障碍（33.3％）时，注意到了实质性的横截面共病，其他物质使用障碍(14.6%)，和焦虑症（10.4%）。目前，三分之二的BPAD患者报告工作中的残疾程度不同（63％），社会(59.3%)，家庭生活（63%）。当前BPAD的治疗差距为70.4%。
■大多数目前患有BPAD的人报告中度-重度残疾。有大量的合并症和很大的治疗差距。这些需要决策者集中努力制定有效的战略。
■NMHS2016是一项具有全国代表性的研究，在2014年至2016年期间在印度12个州进行。一个多阶段，分层，在每个阶段使用基于与大小成比例的概率的随机整群抽样技术。BPAD的诊断基于迷你国际神经精神病学访谈6.0.0。使用Sheehan的残疾量表评估残疾。
■共采访了34,802名成年人。目前BPAD的总体加权患病率为0.3％[95％置信区间（CI）：0.29-0.31]，终生诊断为0.5％（95％CI：0.49-0.51）。男性[优势比（OR）1.56]和居住在城市大都市（OR2.43）的终生诊断为BPAD的风险明显更高。根据MINI6.0.0，在诊断当前的BPAD如烟草使用障碍（33.3％）时，注意到了实质性的横截面共病，其他物质使用障碍(14.6%)，和焦虑症（10.4%）。目前，三分之二的BPAD患者报告工作中的残疾程度不同（63％），社会(59.3%)，家庭生活（63%）。当前BPAD的治疗差距为70.4%。
■大多数目前患有BPAD的人报告中度-重度残疾。有大量的合并症和很大的治疗差距。这些需要决策者集中努力制定有效的战略。
